Skip to main content
. 2020 Nov;12(11):6690–6700. doi: 10.21037/jtd-20-1792

Table 2. Univariate and multivariate analyses of factors associated with overall survival, progression-free survival, and pneumonitis-free survival.

Variables UVA MVA
HR (95% CI) P value HR (95% CI) P value
Overall survival and factors associated
   Age, years 0.963 (0.89–1.04) 0.34
   Race
      White Ref
      Black or African-American 2.44 (0.27–22.2) 0.43
      Other 0 0.99
   Smoking status
      Current smoker Ref
      Former smoker 0.61 (0.07–5.61) 0.663
      Never smoker 0 0.989
   Stage
      IIIA Ref
      IIIB 0.92 (0.15–5.63) 0.93
      Other 0 0.99
   Histology
      Adenocarcinoma Ref
      Squamous 2.04 (0.13–32.9) 0.62
      Non-small cell, NOS 4.45 (0.46–42.9) 0.2
   Total lung-PTV V5 0.98 (0.92–1.04) 0.52
   Total lung-PTV V20 0.95 (0.85–1.06) 0.36
   Total lung mean 0.89 (0.72–1.1) 0.29
   Heart V50 0.96 (0.82–1.13) 0.65
   Number of durvalumab cycles delivered 0.88 (0.77–1.01) 0.64
   Charlson/Deyo Comorbidity Score 0.88 (0.58–1.33) 0.54
Progression-free survival and factors associated
   Age, years 0.932 (0.88–0.98) 0.011** NS
   Race
      White Ref
      Black or African-American 0.49 (0.06–4.00) 0.51
      Other 0.98 (0.12–7.78) 0.98
   Smoking status
      Current smoker Ref
      Former smoker 0.34 (0.07–1.70) 0.19
      Never smoker 0.54 (0.07–4.08) 0.55
   Stage
      IIIA Ref
      IIIB 0.51 (0.14–1.90) 0.32
      Other 0 0.98
   Histology
      Adenocarcinoma Ref
      Squamous 1.44 (0.29–7.3) 0.66
      Non-small cell, NOS 3.83 (0.91–16.1) 0.07
   Number of durvalumab cycles delivered 0.89 (0.82–0.96) 0.002** 0.89 (0.82–0.96) 0.003**
   Charlson/Deyo comorbidity score 0.58 (0.39–0.86) 0.006** 0.55 (0.36–0.86) 0.01**
Pneumonitis-free survival and factors associated
   Age, years 1.05 (0.98–1.13) 0.16
   Smoking status
      Current smoker Ref
      Former smoker 0.61 (0.08–4.94) 0.65
      Never smoker 0.39 (0.02–4.66) 0.38
   Stage
      IIIA Ref
      IIIB 0.46 (0.09–2.17) 0.33
      Other 0 0.98
   Histology
      Adenocarcinoma Ref
      Squamous 0.92 (0.26–3.25) 0.89
      Non-small cell, NOS 0 0.98
   Total lung-PTV V5 0.95 (0.90–0.99) 0.03**
   Total lung-PTV V20 0.96 (0.88–1.05) 0.39
   Total lung mean 0.90 (0.76–1.06) 0.21
   Number of durvalumab cycles delivered 0.92 (0.82–1.03) 0.14
   Charlson/Deyo comorbidity score 1.08 (0.86–1.37) 0.51

No factors were associated with overall survival. The number of durvalumab cycles delivered and comorbidity score were significantly associated with progression free survival on multivariate analysis. Lung V5 was significantly associated with pneumonitis on univariate. ** denotes statistical significance. UVA, univariate; MVA, multivariate; OS, overall survival; PFS, progression free survival; NOS, not otherwise specified; NS, not significant; HR, hazard ratio; CI, confidence interval.